• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Baxter International (BAX) A Bargain On Its CFO Change And Turnaround Moves?

    Simply Wall St·08/22/2026 03:41:26
    Listen to the news

    Why Baxter International’s CFO transition matters for investors

    Baxter International (BAX) is reshaping its senior finance team during a multiyear restructuring, appointing John Rogers as Chief Financial Officer and Executive Vice President from October 1, 2026, with interim arrangements starting in mid September.

    These leadership moves arrive alongside changes to Baxter International’s credit agreement and a US$600 million debt tender offer. Together, they put capital structure, leverage covenants, and cash priorities in sharper focus for shareholders tracking the turnaround.

    See our latest analysis for Baxter International.

    Against this backdrop of finance leadership changes and debt actions, Baxter International’s share price has climbed 21.2% over the past month and 37.3% over the past quarter, while its 1 year total shareholder return of 8.3% contrasts with a 5 year total shareholder return decline of 60.6%. This highlights improving momentum after a long period of weaker outcomes.

    If you are weighing how this kind of restructuring story compares with other market opportunities, it can help to scan a focused group of healthcare related ideas through a screener such as 41 healthcare AI stocks

    Baxter International has a broad, hospital-focused portfolio and a fresh finance team, and the share price has already moved sharply. The key issue now is whether that recent enthusiasm still leaves the stock reasonably valued.

    Most Popular Narrative: 8.3% Undervalued

    The most followed narrative values Baxter International at $28.73 per share compared with the last close at $26.34. This frames the current debate around upside versus execution risk.

    Ongoing portfolio optimization efforts, including divestitures, cost reductions, and a commitment to eliminate stranded costs by 2027, aim to streamline operations, improve efficiency, and drive net margin improvement, which should be reflected in future earnings growth.

    Read the complete narrative.

    Want to see what sits behind that efficiency push and earnings rebuild for Baxter International? The narrative leans on measured revenue progress, margin repair, and a future earnings profile that needs a higher profit base to support the fair value.

    Result: Fair Value of $28.73 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, Baxter International still faces pressure from IV fluid conservation and unresolved margin headwinds, which could quickly challenge the current view that the shares are undervalued.

    Find out about the key risks to this Baxter International narrative.

    Next Steps

    If this Baxter International story appears balanced between risks and rewards, consider reviewing the details for yourself through the 3 key rewards and 1 important warning sign

    Looking for more investment ideas beyond Baxter International?

    If you want to build on what you have learned about Baxter International, now is a good time to widen your watchlist with other focused stock ideas.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.